The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
A holistic, value-based care approach is essential for enhancing quality of life in non-small cell lung cancer patients, focusing on treatment side effects and patient preferences. Treatment history ...